Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of recombinant anti-IL-17A humanized monoclonal antibody injection (608) in adults with active ankylosing spondylitis
CTR20240168Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 608 in ankylosing spondylitis (AS), sponsored by 3S Guojian Pharmaceutical. Started Jan 2024; status: completed.
02
Drugs
608
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20240168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240168.